Abstract

Achieving and sustaining low disease activity (LDA) and remission in rheumatoid arthritis (RA) remains challenging. This study examined the rates and predictors of LDA/remission and sustained LDA/remission in an Indonesian RA cohort. A retrospective study of newly diagnosed adult patients attending a rheumatology clinic in 2020-2021 was conducted. Patients were followed for 12 months to evaluate achievement of LDA/remission, defined as DAS28-ESR ≤3.2, and those meeting the target were observed for an additional 12 months to evaluate sustained LDA/remission. Cox regression was used to identify predictors of time to LDA/remission and loss of LDA/remission. Of 166 participants, 91 (54.8%) achieved LDA/remission, with a median time of 10 months. Among these, 39 (41.8%) maintained LDA/remission for 12 months. The median time to loss of LDA/remission was also 10 months. In multivariate analysis, no baseline variables (age, sex, rheumatoid factor (RF) positivity, disease activity, obesity, or disease duration) predicted achieving or sustaining LDA/remission. In this Indonesian cohort, over half of patients reached LDA/remission within 12 months. However, fewer than half sustained it over the following year, highlighting the need for ongoing monitoring and timely treatment adjustments, even after remission is achieved.

References

1. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4 (1): 18001. DOI: 10.1038/nrdp.2018.1.

2. Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023; 5 (10): e594–e610. DOI: 10.1016/S2665-9913(23)00211-4.

3. Yu C, Jin S, Wang Y, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: A systematic review and meta-analysis. Clin Rheumatol. 2019; 38: 727–738. DOI: 10.1007/s10067-018-4340-7.

4. Aletaha D, Alasti F, Smolen JS. Optimisation of a Treat-To-Target approach in rheumatoid arthritis: Strategies for the 3-month time point. Ann Rheum Dis. 2016; 75: 1479–185. DOI: 10.1136/annrheumdis-2015-208324.

5. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023; 82: 3–18. DOI: 10.1136/ard-2022-223356.

6. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021; 73 (7): 924–939. DOI: 10.1002/acr.24596.

7. Heckert SL, Maassen JM, Nevins I, et al. Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies. Rheumatol. 2025; 64 (3): 1052-1059. DOI: 10.1093/rheumatology/keae212.

8. O’Neil LJ, Alpízar-Rodríguez D, Deane KD. Rheumatoid Arthritis: The Continuum of Disease and Strategies for Prediction, Early Intervention, and Prevention. J Rheumatol. 2024; 51 (4): 337–349. DOI: 10.3899/jrheum.2023-0334.

9. Morin S, Segafredo G, Piccolis M, et al. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: Considerations, requirements, and opportunities. Lancet Glob Health. 2023; 11 (1): e145–e54. DOI: 10.1016/S2214-109X(22)00460-0.

10. Jain A, Joseph S, James J, et al. Delay in diagnosis of rheumatoid arthritis: Reasons and trends over a decade. Rheumatol Int. 2022; 43: 503–508. DOI: 10.1007/s00296-022-05187-0.

11. Naeem F, Anwer khan SE, Saeed MA, et al. Diagnostic and therapeutic delay in Rheumatoid Arthritis patients: Impact on disease outcome. Pak J Med Sci. 2021; 37 (4). DOI: 10.12669/pjms.37.4.3471.

12. Chandrashekara S, Shobha V, Dharmanand BG, et al. Factors influencing remission in rheumatoid arthritis patients: Results from Karnataka rheumatoid arthritis comorbidity (KRAC) study. Int J Rheum Dis. 2018; 21 (11): 1977–1985. DOI: 10.1111/1756-185X.12908.

13. Sun X, Li R, Cai Y, et al. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health West Pac. 2021; 15: 100240. DOI: 10.1016/j.lanwpc.2021.100240.

14. Steunebrink LMM, Vonkeman HE, ten Klooster PM, et al. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: Results from the DREAM registry. Clin Rheumatol. 2016; 35: 609–615. DOI: 10.1007/s10067-016-3191-3.

15. Alveyn E, Coalwood C, Farrell G, et al. Trends in remission rates for rheumatoid arthritis in England and Wales: A population-level cohort study. Rheumatol. 2025; 64 (9): 4957-4967. DOI: 10.1093/rheumatology/keaf233.

16. Xie W, Li J, Zhang X, et al. Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018. Int J Rheum Dis. 2019; 22 (9): 1670–1678. DOI: 10.1111/1756-185X.13651.

17. Pope JE, Movahedi M, Rampakakis E, et al. ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: Data from the Ontario Best practices Research Initiative (OBRI). RMD Open. 2018; 4 (2): e000738. DOI: 10.1136/rmdopen-2018-000738.

18. Al-Saleh J, Almarzooqi A, Negm AA. Prevalence and Predictors of Remission and Sustained Remission in Patients with Rheumatoid Arthritis from the United Arab Emirates: A Two-Year Prospective Study. Open Access Rheumatol. 2023; 15: 51–63. DOI: 10.2147/OARRR.S408894.

19. Liu Y, Hazlewood GS, Kaplan GG, et al. Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis. Arthritis Care Res. 2017; 69 (2): 157–165. DOI: 10.1002/acr.22932.

20. Abuhelwa AY, Hopkins AM, Sorich MJ, et al. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs. Sci Rep. 2020; 10: 18634. DOI: 10.1038/s41598-020-75673-7.

21. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatol. 2012; 51 (suppl 6): vi5–vi9. DOI: 10.1093/rheumatology/kes279.

22. Okawa Y, Mitsuhashi T, Tsuda T. The Asia-Pacific Body Mass Index Classification and New-Onset Chronic Kidney Disease in Non-Diabetic Japanese Adults: A Community-Based Longitudinal Study from 1998 to 2023. Biomed. 2025; 13 (2): 373. DOI: 10.3390/biomedicines13020373.

23. Canhão H, Rodrigues AM, Gregório MJ, et al. Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. Front Med. 2018; 5: 40. DOI: 10.3389/fmed.2018.00040.

24. Tasamma AT, Eshetu BZ, Seyoum AT, et al. Differences in rates of remission between rheumatoid factor positive and negative rheumatoid arthritis patients: Experience from a resource-limited setting. Clin Rheumatol. 2025; 44: 1505–1511. DOI: 10.1007/s10067-025-07370-7.

25. Thomas K, Lazarini A, Kaltsonoudis E, et al. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: Data from 1317 patients. Ther Adv Musculoskelet Dis. 2020; 12. DOI: 10.1177/1759720X20937132.

26. Gildemeister N, Redeker I, Buehring B, et al. Prevalence of remission in patients with rheumatoid arthritis in daily clinical practice: Long-term data from a tertiary care centre. Clin Exp Rheumatol. 2024; 42 (7): 1407–1415. DOI: 10.55563/clinexprheumatol/66rnqb.

27. Rannio T, Asikainen J, Kokko A, et al. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis. J Rheumatol. 2016; 43 (4): 699–706. DOI: 10.3899/jrheum.141480.

28. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75: 3–15. DOI: 10.1136/annrheumdis-2015-207524.

29. Schipper LG, Fransen J, den Broeder AA, et al. Time to achieve remission determines time to be in remission. Arthritis Res Ther. 2010; 12: R97. DOI: 10.1186/ar3027.

30. Einarsson JT, Willim M, Ernestam S, et al. Prevalence of sustained remission in rheumatoid arthritis: Impact of criteria sets and disease duration, a Nationwide Study in Sweden. Rheumatol. 2019; 58 (2): 227–236. DOI: 10.1093/rheumatology/key054.

31. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: Latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017; 9 (10): 249–262. DOI: 10.1177/1759720X17720366.

32. Yılmaz V, Umay E, Gündoğdu İ, et al. Rheumatoid Arthritis: Are psychological factors effective in disease flare? Eur J Rheumatol. 2019; 4 (2): 127–32. DOI: 10.5152/eurjrheum.2017.16100.

33. Han J, Geng Y, Deng X, et al. Subclinical Synovitis Assessed by Ultrasound Predicts Flare and Progressive Bone Erosion in Rheumatoid Arthritis Patients with Clinical Remission: A Systematic Review and Metaanalysis. J Rheumatol. 2016; 43 (11): 2010–8. DOI: 10.3899/jrheum.160193.

34. King K, McGuinness S, Watson N, et al. What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials. Patient Prefer Adherence. 2023; 17: 3265–3303. DOI: 10.2147/PPA.S424024.

35. Zanetti A, Zambon A, Scirè CA, et al. Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: A prospective cohort study from the ELECTRA database. Ther Adv Musculoskelet Dis. 2023; 15. DOI: 10.1177/1759720X231194179.

36. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: Interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016; 75 (1): 45–51. DOI: 10.1136/annrheumdis-2014-206439.

37. Khader Y, Beran A, Ghazaleh S, et al. Predictors of remission in rheumatoid arthritis patients treated with biologics: A systematic review and meta-analysis. Clin Rheumatol. 2022; 41: 3615–3627. DOI: 10.1007/s10067-022-06307-8.

38. Yip K, Navarro-Millán I. Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Curr Opin Rheumatol. 2021; 33 (2): 117–121. DOI: 10.1097/BOR.0000000000000782.

Download

Included in

Epidemiology Commons

Share

COinS